New hints towards a precision medicine strategy for IDH wild-type glioblastoma.

Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wild-type glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell technologies and computational approaches.
Competing Interests: Disclosure AI reports grants and travel funding from Carthera, research grants from Transgene, Sanofi, Air Liquide and Nutritheragene travel funding from Leo Pharma, grants from outside the submitted work. All remaining authors have declared no conflicts of interest.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)